alpha 2 adrenergic receptor Agonists
1 drugsAbout alpha 2 adrenergic receptor
The alpha-2 adrenergic receptor (ADRA2A) modulates neurotransmitter release and is involved in various physiological processes. It is a G protein-coupled receptor that responds to catecholamines like norepinephrine and epinephrine.
Human genetics provide moderate support for ADRA2A as a therapeutic target, with variants linked to lipodystrophy (score 0.55), abnormal nasolacrimal system morphology (0.53), and type 2 diabetes (0.44). Loss-of-function variants are associated with increased risk of type 2 diabetes, suggesting activation may be beneficial.
ADRA2A is targeted by 17 FDA-approved small molecule drugs, including IGALMI, BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, and ALPHAGAN P. These drugs span therapeutic areas including CNS disorders, ophthalmology, and other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Refractive Error with only 1 trials.
Human Genetic Evidence Moderate
Genetic evidence shows moderate support for ADRA2A, with a max score of 0.55 linking it to lipodystrophy.
Further investigation of ADRA2A's role in lipodystrophy could reveal novel therapeutic opportunities.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 1 traits
- • Strong signal in endocrine system disease, nutritional or metabolic disease, phenotype pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
3 totalGWAS and other genetic studies link ADRA2A to 3 diseases.
🔗 Colocalization Evidence 3 strong
max H4: 0.95eQTL/pQTL signals for ADRA2A colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Fourteen companies have approved drugs targeting ADRA2A, with Novartis and Fresenius Kabi among the top players.
The fragmented competitive landscape suggests relatively low barriers to entry for new ADRA2A-targeting drugs.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 2 adrenergic receptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Clinical Trials 91 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 14 | 1 | 2 | 93% |
| Phase 2 | 21 | 13 | 4 | 4 | 76% |
| Phase 3 | 26 | 22 | 2 | 2 | 92% |
| Phase 4 | 27 | 21 | 3 | 3 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2013 - 2013)
The first ADRA2A-targeting drug was approved in 1996 (REMERON), with the most recent approval in 2024 (ONYDA XR).
The continued approval of new drugs indicates sustained interest and potential for further development in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 46 clinical trials targeting alpha 2 adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities